Axa’s Filana Therapeutics FLNA Stock Holding History

Axa’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-3,693	Closed	-$101K	–	1467
2014 Q3	$101K	Buy	+3,693	New	+$112K	﹤0.01%	1304

Other funds holding FLNA

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Axa's FLNA Position: Q4 2014 in Review

Axa sold out of Filana Therapeutics (FLNA) in Q4 2014, closing a stake of 3,693 shares — an estimated $101K sold.

Axa first reported a position in FLNA in Q3 2014 and held it in 1 quarter. The position peaked at $101K in Q3 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q4 2014.

Axa reported no remaining Filana Therapeutics position as of Q4 2014 after selling out during the quarter.
Axa sold 3,693 Filana Therapeutics shares in Q4 2014, an estimated $101K.
Axa first reported a position in Filana Therapeutics in Q3 2014 and held it in 1 quarter.
Axa's Filana Therapeutics position peaked at $101K in Q3 2014.
66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2014.

Based on Axa's 13F filing for Q4 2014, filed 13 Feb 2015.